Jul. 14 at 1:55 PM
💰 How
$NVAX is quietly building a high-margin royalty business beyond COVID vaccines
Novavax's proprietary Matrix-M adjuvant is gaining traction as more vaccine makers look to enhance immune responses without developing their own platform.
Key developments:
•
$SNY received a license to use Matrix-M in additional vaccines, with Novavax eligible for up to
$210M in milestones plus royalties
•
$PFE secured rights to Matrix-M in up to two disease areas under a deal worth up to
$530M
• Multiple partners are now evaluating Matrix-M across infectious disease and oncology programs
• Future licensing deals could generate recurring revenue through upfront payments, milestones, royalties and supply agreements
See the upside Wall Street expects for
$NVAX. 👇 https://www.zacks.com/stock/research/NVAX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38772&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38772
